

# Molecular analysis of multifocal prostate cancer cases

Rasa Sabaliauskaitė<sup>1</sup>,

Donatas Petroška<sup>2,3</sup>,

Darius Dasevičius<sup>2,3</sup>,

Arvydas Laurinavičius<sup>2,3</sup>,

Feliksas Jankevičius<sup>2,4</sup>,

Juozas R. Lazutka<sup>1</sup>,

Sonata Jarmalaitė<sup>1</sup>

<sup>1</sup>Faculty of Natural Sciences,  
Vilnius University

<sup>2</sup>Faculty of Medicine,  
Vilnius University

<sup>3</sup>National Centre  
of Pathology, Vilnius

<sup>4</sup>Urology Department,  
Vilnius University Hospital  
Santariskiu Clinics, Vilnius,  
Lithuania

**Background.** Prostate cancer (PCa) is usually a multifocal disease with different foci displaying histological and molecular heterogeneity. Biopsy-based pathology diagnosis of PCa may not be representative of the entire tumour; thus, markers more precisely characterizing every focus of multifocal PCa are highly instrumental for a better testing of PCa.

**Materials and Methods.** Two distant foci of prostate adenocarcinoma were obtained from prostatectomy specimens of ten patients with pT2–pT3 stage PCa. The expression of *TMPRSS2 : ERG*, *TMPRSS2 : ETV1*, and *TERT* was assessed by means of reverse transcription PCR and quantified using the real-time-based approach. Ki-67, ERG, EMA, AMACR, p16, and p53 expression was evaluated by means of immunohistochemistry (IHC) on tissue microarrays (TMA).

**Results.** Two out of ten cases were identified with different Gleason scores in paired foci of PCa. The expression of most of the IHC markers was quite even between TMA cores of each PCa case, with p16 showing the highest level of heterogeneity (44%; 4/9); 80% (8/10) of multifocal PCa expressed different variants of the *TMPRSS2 : ERG* transcript or showed a varying status of fusion positivity in paired foci, and the expression levels of the transcript were also heterogeneous. Similarly, 90% (9/10) of PCa showed a different positivity for *TERT* expression in paired foci.

**Conclusions.** Measurement of *TMPRSS2 : ERG* and *TERT* expression offers a valuable tool for identifying most aggressive tumour foci and selecting a relevant treatment of PCa.

**Key words:** prostate cancer, multifocality, *TMPRSS2 : ERG*, telomerase

## INTRODUCTION

Prostate cancer (PCa), the most common cancer in men, usually is a multifocal disease with different foci displaying a marked histological and molecular heterogeneity. More than 80% of prostates have been shown to possess two or more separate tumours at the time of clinical diagnosis of PCa (1). Decision on PCa treatment is usually

based on the analysis of a small biopsy section. Due to multifocality, a biopsy specimen may not be representative of the entire tumour, and a set of cases can be under- or over-treated. Radical prostatectomy, usually used for the treatment of PCa, although highly effective, is associated with significant morbidity. Over-treatment of localized PCa may be avoided by using minimally invasive means, such as focal therapy (2). Multiple studies (reviewed in (3)) indicate that the current diagnostic modalities, including PSA test, biopsy or imaging, are not efficient enough to distinguish unifocal cases from a multifocal disease. Molecular biomarkers, such as genetic aberrations

Correspondence to: Sonata Jarmalaitė, Division of Human Genome Research Centre, Faculty of Natural Sciences, Vilnius University, M. K. Čiurlionio 21, Vilnius LT-03101, Lithuania. E-mail: sonata.jarmalaitė@gf.vu.lt

tions and epigenetic changes, are extensively studied for an improved prognosis of PCa. Comparison of molecular profiles of multifocal PCa cases is also an important tool for a better understanding of the molecular basis of multifocal cancer.

In PCa, a frequent occurrence of gene fusion between the 5' untranslated region of *TMPRSS2* (transmembrane protease, serine 2) and the 3' region of genes of the *ETS* family, including *ERG* (*v-ets* erythroblastosis virus E26 oncogene homolog (avian)) or *ETV1* (*ets* variant 1), has recently been identified (4). Fusion of transcription factors of the *ETS* family to androgen-inducible *TMPRSS2* promoter causes an over-expression of these oncogenic proteins. The *TMPRSS2 : ERG* fusion is the most prevalent form of fusions in PCa and is detectable in almost half of all PCa, independently of the stage or grade (4). Multifocal PCa may harbour different foci that may be *TMPRSS2 : ERG* positive or *TMPRSS2 : ERG* negative, and for identification of the fusion positivity information from all significant foci is indispensable. Several recent studies (5–9) showed significant associations between *TMPRSS2 : ERG* positivity and the aggressive course of PCa; thus, identification of *TMPRSS2 : ERG* status in prostate tumours may assist in the stratification of PCa cases for a relevant treatment.

Many other molecular alterations, in addition to *TMPRSS2 : ETS* fusions, have been discovered in PCa in the recent years. Inactivation of tumour suppressor genes, including *PTEN*, *GSTP1*, *CDKN2A* and *TP53*, as well as activation of oncogenic proteins *ERG*, *MYC* and telomerase, are among the most predominant molecular alterations identified in prostate tumours (10). For a better understanding of the molecular basis of PCa, paired foci were selected from 10 cases with multifocal PCa. One of the foci from these pairs of tumours was included in our previous study (11) on a wide range of PCa molecular biomarkers; however, PCa multifocality was not addressed in that assay. In the present study, we analyse the most informative genetic biomarkers selected during our previous investigations and immunohistochemical biomarkers selected from recent publications (12–18) based on their diagnostic or prognostic value in PCa. The expression of fusion transcripts *TMPRSS2 : ERG* and *TMPRSS2 : ETV1*, reactivation of the catalytic subunit of telomerase (*TERT*), expression of the tumour suppressor proteins p16 (encoded by *CDKN2A*) and p53 (encoded by *TP53*), expression of the oncogenic transcription factor *ERG*, epithelial membrane antigen (EMA), and alpha-methylacyl coenzyme A racemase (AMACR) are analysed in the present study in paired foci of PCa cases. In addition, the cell proliferation marker Ki-67 and clinical variables (pT, Gleason score, preoperative PSA value) are assessed for their potential to characterise multifocal prostate tumours.

## MATERIALS AND METHODS

**Sample collection.** Ten cases with multifocal tumours were selected from the large group of PSA-screened and biopsy-proven PCa cases collected during January 2008 – August 2009 at the Urology Department of the Vilnius University Hospital Santariskiu Clinics and treated by radical prostatectomy. The selection of cases was based on the availability of a sufficient amount of tumour tissue for the assessment of multiple biomarkers in two foci. Approval from the local Bioethics Committee had been obtained before initiating the study, and all patients gave informed consent for participation. After radical prostatectomy, unfixed prostate tissue was immediately transported to the Pathology Department. Adenocarcinoma was located by palpation, and cores of 0.8 cm in diameter were punched out by a large core instrument with a circular blade. One of the two punches was taken from the right and the other from the left side of the prostate, or in some cases from the basal and apical regions of the same side. The distance between multifocal tumours was 3 mm or more. The taken core was immediately frozen in liquid nitrogen. Histological sections and the staining of the same core were performed by standard procedures and evaluated by a pathologist.

The selected cases were diagnosed with pT2–pT3 tumours and were graded mainly as having the Gleason score 6 or 7 (Table 1). The mean age of the group was  $63.2 \pm 1.6$  years and the mean preoperative PSA level  $6.0 \pm 0.8$  ng/ml (for one case this information was missing); one case (1/10) experienced PSA-based (biochemical) progression during two months after surgery.

**Tissue-arrays and immunohistochemistry.** Tissue microarrays (TMA) were constructed from each patient's archival formalin-fixed, paraffin-embedded donor block (DB) and were assembled in a recipient block (19, 20). The paraffin DB containing the largest focus of tumour was identified in a diagnostic haematoxylin/eosin stained slide. This slide was scanned with the Aperio ScanScope XT System (Aperio Technologies, Vista). The benign and cancer areas were marked with annotations by the pathologist on a virtual slide. From this section, the corresponding regions on the paraffin DB were identified, enabling TMA cores to be taken using an automated tissue arrayer (3DHISTECH, TMA Master, Budapest, Hungary). The core diameter was 1.0 mm, with a depth of 3 mm.

Cut TMA sections (4  $\mu$ m) were dried, deparaffinised, and rehydrated through descending concentrations of ethanol and prepared for antigen retrieval and immunohistochemistry (IHC) staining. Heat-mediated antigen retrieval was done using microwave treatment for  $2 \times 5$  min in a citrate buffer before being processed either in the Ventana Benchmark system (Ventana Medical Systems, Inc.)

Table 1. Comparison of *TMPRSS2 : ERG* (status, transcript variants and expression levels) and *TERT* expression in multifocal prostate tumours

| Case No. | pT stage | Sample 1      |                                    |                         |                                    | Sample 2      |                                    |                         |                                    |
|----------|----------|---------------|------------------------------------|-------------------------|------------------------------------|---------------|------------------------------------|-------------------------|------------------------------------|
|          |          | Gleason score | Expression of <i>TMPRSS2 : ERG</i> |                         | Expression of <i>TERT</i> (RT-PCR) | Gleason score | Expression of <i>TMPRSS2 : ERG</i> |                         | Expression of <i>TERT</i> (RT-PCR) |
|          |          |               | Type of transcript                 | Expression level (QPCR) |                                    |               | Type of transcript                 | Expression level (QPCR) |                                    |
| 1        | pT3a     | 3 + 4         | T1 / E4 and T2 / E4                | 1                       | Yes                                | 3 + 3         | T1 / E4                            | 1                       | Yes                                |
| 2        | pT2c     | 3 + 3         | T1 / E4 and T2 / E4                | 1                       | No                                 | 3 + 3         | T1 / E4                            | 2                       | Yes                                |
| 3        | pT2b     | 3 + 3         | T1 / E4 and T2 / E4                | 1                       | No                                 | 3 + 4         | T1 / E4                            | 1                       | Yes                                |
| 4        | pT3b     | 3 + 4         | T1 / E4                            | 1                       | No                                 | 3 + 4         | T1 / E4                            | 2                       | Yes                                |
| 5        | pT2b     | 3 + 3         | T1 / E4                            | 1                       | No                                 | 3 + 3         | T1 / E4                            | 1                       | Yes                                |
| 6        | pT2b     | 3 + 3         | T1 / E4 and T2 / E4                | 1                       | Yes                                | 3 + 3         | wt                                 | –                       | No                                 |
| 7        | pT2b     | 3 + 3         | T1 / E1                            | 1                       | No                                 | 3 + 3         | T1 / E4                            | 2                       | Yes                                |
| 8        | pT2b     | 3 + 3         | T1 / E4                            | 1                       | No                                 | 3 + 3         | T1 / E4 and T2 / E4                | 1                       | Yes                                |
| 9        | pT2b     | 3 + 3         | wt                                 | –                       | No                                 | 3 + 3         | T1 / E4                            | 1                       | Yes                                |
| 10       | pT3a     | 3 + 4         | T1 / E4                            | 1                       | No                                 | 3 + 4         | T1 / E4 and T2 / E4                | 2                       | Yes                                |

QPCR – quantitative polymerase chain reaction; RT-PCR – reverse transcription polymerase chain reaction.

Differences between paired foci are marked in grey. For *TMPRSS2 : ERG*, heterogeneity of fusion status but not the variant transcripts are marked.

*TMPRSS2 : ERG* expression levels: 1 – low level (>5.71); 2 – high level (<5.7); relative quantitation of the product was done using *GAPDH* as endogenous control.

using a prediluted antibody to EMA, p16, p53, AMACR, or in the Dako Techmate 500 system (Dako) for Ki-67 and in the DakoLink for ERG. IHC analysis was performed on 4 µm sections using DakoCytomation antibodies to the monoclonal mouse anti-human Ki-67 antigen, clone MIB-1; monoclonal mouse anti-human p53 antigen, clone DO-7; monoclonal mouse anti-human EMA antigen, clone E29; monoclonal mouse anti-human p16 antigen, clone E6H4 (CINTec Histology Kit). 3,3'-Diaminobenzidine was used as a chromogenic substrate. The prediluted antibody to rabbit monoclonal *TMPRSS2-ERG* antigen (clone EPR3864; Epitomics) was processed with an EnVision FLEX system.


All IHC slides were counterstained using haematoxylin. All stainings were performed with the subsequent positive control of an appropriate antibody.

The expression of IHC biomarkers (Fig. 1) was evaluated in an appropriate site of a cell (nucleus, cytoplasm or membrane) and classified as positive or negative (value 1 or 2 in Table 2). Expression of AMACR was scored as negative (1), middle (2) or strong (3). The mean value of the Ki-67 proliferation index (PI) was calculated as the percentage of positively stained nuclei from all PCa nuclei in cores, and the range was evaluated as the largest difference between the PI of the two cores.

Table 2. Immunohistochemistry values and heterogeneity status

| Case No. | Ki-67   |          | ERG   |               | EMA   |               | p16   |               | p53   |               | AMACR |               |
|----------|---------|----------|-------|---------------|-------|---------------|-------|---------------|-------|---------------|-------|---------------|
|          | Mean, % | Range, % | Value | Heterogeneity | Value | Heterogeneity | Value | Heterogeneity | Value | Heterogeneity | Value | Heterogeneity |
| 1        | 8       | 1        | –     | –             | 1     | No            | 2     | Yes           | 2     | Yes           | 2     | Yes           |
| 2        | 6       | 3        | 2     | No            | 1     | No            | 1     | No            | 1     | No            | 3     | No            |
| 3        | 5       | 4        | –     | –             | 1     | No            | 2     | No            | 1     | No            | 3     | No            |
| 4        | 2       | 4        | 2     | No            | 1     | No            | 2     | No            | 1     | Yes           | 3     | No            |
| 5        | 1       | 1        | 2     | No            | 1     | No            | 2     | Yes           | 1     | No            | 2     | No            |
| 6        | 1       | 7        | 1     | No            | 1     | No            | 2     | No            | 1     | No            | 2     | No            |
| 7        | 7       | 6        | 2     | No            | 2     | No            | 2     | Yes           | 1     | No            | 3     | No            |
| 8        | 2       | 1        | 1     | No            | 1     | No            | 2     | No            | 1     | No            | 3     | No            |
| 9        | 9       | 1        | 2     | No            | 1     | No            | 2     | Yes           | 1     | No            | 3     | No            |

1 – no staining, 2 – positive for staining. Differences between paired foci are marked in grey. The range was evaluated as the largest difference between Ki-67 proliferation indexes of two cores.




**Fig. 1.** Examples of different immunohistochemical staining in tissue microarray cores: *a* – EMA-negative prostate cancer (PCa), *b* – EMA-positive PCa epithelium, *c* – p16-negative PCa glands, *d* – p16-positive PCa cells, *e* – AMACR-negative cytoplasm of PCa cells, *f* – AMACR-positive cytoplasm of PCa cells, *g* – some Ki67-positive PCa cell nuclei, *h* – some p53-positive PCa cell nuclei

#### Transcript identification by reverse transcription-PCR.

Total RNA was extracted from the frozen tumour tissues by the phenol/chloroform method. Genomic DNA was removed by treatment with DNase I (Fermentas Thermo Scientific). RNA was dissolved in RNase-free water, and RNA quality was checked using electrophoresis on a 1% agarose gel; RNA was quantified on NanoDrop 1000 (Thermo Scientific).

For the reverse transcription-PCR (RT-PCR) analysis, the *TMPRSS2*:*ERG* fusion transcript was amplified with the primers described by Tomlins et al. (21), covering the most frequently fused exons (exons 1–2 of *TMPRSS2* and exon 4 of *ERG*): *TMPRSS2* 5'-CAGGAGGCGGAGGCGGA-3',

*ERG* 5'-GTAGGCACACGACTGG-3'. *TMPRSS2*:*ERG*-negative cases were additionally analysed for expression of the *TMPRSS2*:*ETV1* transcript. The primer pair (21) included the same sense *TMPRSS2* gene primer as used in the *TMPRSS2*:*ERG* assay and the antisense primer covering the exon 4 of *ETV1* gene (5'-CAGGCCATGAAAACCTT-3'). The *GAPDH* (glyceraldehyde-3-phosphate dehydrogenase) gene was used as endogenous control for fused gene expression, and the product was amplified with the following primer set: univdir*GAPDH* 5'-CAAGGTCATC-CATGACAACCTT-3' and univrev*GAPDH* 5'-GTCCAC-CACCTGTTGCTGTAG-3'.



**Fig. 2.** Example of *TMPRSS2 : ERG* analysis by RT-PCR in two prostate tumour foci (A and B). '+' in the gels presents the reaction with reverse transcriptase, '-' – the reaction without reverse transcriptase; the numbers 1, 2, 3 and 4 correspond to cases 6, 7, 3 and 9 in Table 1. M – size marker

For detection of the *TERT* transcript, primers were selected from Boltze et al. (22): *TERT*-dir 5'-CGGAA-GAGTGTCTGGAGCAA-3', *TERT*-rev 5'-GGATGAAGCG-GAGTCTGGA-3'. As an additional control, *TR* was amplified along with *TERT*, using the following set of primers: *TR*-dir 5'-CCTAACTGAGAAGGGCGTAGGC-3', *TR*-rev 5'-CTAGAATGAACGGTGGGAAGGCG-3'.

In RT-PCR, 1 µg of total RNA from tissue was reverse-transcribed into cDNA using the Maxima® First Strand cDNA Synthesis Kit for RT-qPCR (Fermentas Thermo Scientific) in the final volume of 20 µl. The reverse transcription product was amplified on Mastercycler ep gradient S (Eppendorf) in the following conditions: 95 °C for 4 min, followed by 94 °C for 1 min, annealing at 58 °C for 45 s and 72 °C for 45 s repeated 35 times, and the final elongation at 72 °C for 10 min. A negative control without reverse transcription was included for each sample, and multiple water controls were included in each run. RT-PCR products were resolved by electrophoresis on 2% agarose gels (Fig. 2). The presence of the RT-PCR product (*TMPRSS2 : ERG*, *GAPDH*, *TERT* or *TR*) was scored as positivity for the corresponding transcript (Table 1).

To identify the exact point of fusion, a set of *TMPRSS2 : ERG* transcripts of different length were sequenced on a 3130XL Genetic Analyzer (Applied Biosystems) using a cloned product (InsTAclone™ PCR Cloning Kit; Fermentas Thermo Scientific) and the v2.0 kit (Applied Biosystems) for sequencing reaction. In sequence analysis, the nucleotide numbering of the *TMPRSS2* gene is based on cDNA sequence with the GeneBank number NM\_005656 and for the *ERG* gene NM\_004449.

***TMPRSS2 : ERG* quantification.** The fused gene expression was quantified by using SYBR Green labelling and the pairs of primers described previously (21). The QPCR reaction was performed using Maxima™ SYBR Green QPCR Master

Mix (Fermentas Thermo Scientific), with 1 U/µl of Uracil-DNA Glycosylase (Fermentas Thermo Scientific), 300 mol/l forward and reverse primers in the total volume of 25 µl. The PCR cycles on the ABI Prism 7500 Fast Real-time PCR System (Applied Biosystems) consisted of 50 °C for 2 min, 95 °C for 10 min, followed by 95 °C for 15 s and 60 °C for 1 min, repeated in 40 cycles, and the melting step. Threshold cycle (ct) values for each sample were generated during the exponential phase of QPCR, and  $\Delta$ ct values were calculated using *GAPDH* as an internal control. According to the median  $\Delta$ ct value, the expression level of the *TMPRSS2 : ERG* transcript was dichotomized into high (<5.7) and low (>5.71; Table 1).

**Statistical analysis.** Statistical analysis was carried out using GagraphPad InStat software. Correlations were evaluated by Spearman's test. Two-sided Fisher's exact test was used for comparison of categorical values and the Mann-Whitney test for continuous values. The p value <0.05 was considered significant.

## RESULTS

**Clinical and IHC characteristics of paired foci.** A total of 20 tumour foci from 10 radical prostatectomy specimens were analysed in our study. Eight pairs of multifocal tumours had an identical Gleason score, while two cases had tumours with different Gleason scores (Table 1). The expression of most of the IHC markers was quite even between TMA cores of each PCa case. *EMA* and *ERG* were homogeneously expressed in all pairs of cores (9/9 and 7/7, respectively; Table 2). TMA pairs showed a less uniform expression of p53 and AMACR proteins: 2 out of 9 (22%) and 1 out of 9 (11%) TMA pairs showed expression heterogeneity, respectively. Four out of 9 (44%) TMA pairs were heterogeneous according to positivity for the

p16 protein. The Ki-67 PI range variation was from 1% to 7% among cores when the Ki-67 PI mean value was 1–9% among different cases. No statistically significant correlations were identified between the status of heterogeneity of a particular IHC marker and *TMPRSS2 : ERG*, *TERT* expression or PCa clinical variables. However, an association was observed between the occurrence of *TMPRSS2 : ERG* fusion and immunohistochemically detectable expression of *ERG*: two out of seven PCa cases were negative for *ERG* expression in IHC (Table 2), and both cases showed a low production of the *TMPRSS2 : ERG* transcript in the QPCR assay or were negative for *TMPRSS2 : ERG* in RT-PGR (Table 1).

**Genetic characteristics of paired foci.** Overall, 18 out of 20 tumour foci expressed the *TMPRSS2 : ERG* fusion product. *TMPRSS2 : ERG* expression was detected in 8 PCa in both foci, while two cases expressed the fusion transcript only in one focus (2 / 10; 20% heterogeneity for the fusion status). No *TMPRSS2 : ETV1* transcript was detected in these two foci. According to the type of *TMPRSS2 : ERG* transcripts, the fusion between the first exon of *TMPRSS2* and the fourth exon of *ERG* prevailed (85%) in our study; 11 (55%) foci expressed T1 / E4 as a single transcript and 6 foci together with the T2 / E4 transcript variant (30%). One case was identified with the T1 / E1 transcript in the first focus and with the T1 / E4 in the second focus. An identical set of *TMPRSS2 : ERG* transcripts was detected in paired foci from two prostate carcinomas; thus, the heterogeneity of the fusion isoform was 75% (6/8). Assessment of the *TMPRSS2 : ERG* transcript expression levels revealed an additional level of heterogeneity. Notable differences ( $p < 0.0001$ ) were identified between paired foci, with only 4 out of 8 pairs showing a similar intensity of fusion expression (Table 1). Thus, the heterogeneity of the transcription level was 50%.

Measurement of *TERT* expression was also helpful in verifying the molecular heterogeneity of multifocal tumours: only one case of PCa had an identical status for *TERT* expression in both foci (90% heterogeneity; Table 1). Expression of the *TERT* transcript was predominant in *TMPRSS2 : ERG*-positive foci with 100% (11 / 11) of *TERT*-positive cases concurrently having the fusion transcript (Table 1); however, the association was not statistically significant. Similarly, foci with low *TMPRSS2 : ERG* expression levels (50%; 7 / 14) were negative for *TERT*, while the cases showing a high *TMPRSS2 : ERG* expression (100%; 4 / 4) were also *TERT*-positive.

One case (No. 10) of biochemical disease progression was identified in this pilot study. A high *TMPRSS2 : ERG* expression level as well as positivity for *TERT* transcript were detected in one tumour focus, while another focus showed a low production of *TMPRSS2 : ERG* transcript and was *TERT*-negative.

## DISCUSSION

Multifocal PCa has been reported in up to 91% of all cases of radical prostatectomy (1, 2). Some investigators (reviewed in 1) have reported that increased numbers of tumour foci and larger volumes of index and nonindex tumours are correlated with a more aggressive outcome of PCa. However, the currently approved PCa biomarkers, including the preoperative PSA value, are not potent predictors of multifocality, and sensitive markers for the identification of multifocal PCa are highly instrumental. In our study, 8 out of 10 pairs of foci from multifocal PCa expressed different variants of the *TMPRSS2 : ERG* transcript or showed a variable status of fusion positivity. Similarly, 90% of multifocal tumours showed a distinct status of *TERT* expression (positive or negative) in both foci. Different Gleason scores were identified in two PCa cases, but most of the IHC biomarkers showed low levels of heterogeneity between the foci.

The morphological difference of tumours is mainly characterized by the Gleason score. Arora et al. (23) showed that only 9 of 100 prostatectomy specimens had the same Gleason score in all the foci studied. In another study (24), more than half of prostates contained at least three different grades of cancer, and the number of different grades increased with increasing tumour volume. In our study, different Gleason scores were identified in two pairs of tumours with multifocal PCa. The cell proliferation index, determined by Ki-67 expression, was 1–9% among different cases of PCa, and a certain variation (up to 7%) was observed in paired PCa tissues. Other IHC biomarkers, except p16, showed quite a homogeneous expression in separate foci; 44% of paired tumour foci had a varying p16 expression. There are limited data in the literature on the heterogeneity of IHC markers in PCa. Borre et al. (25) reported some level of heterogeneity of the p53 protein expression in prostate tissue. Our study on the ERG protein expression, conducted in a larger group of PCa cases (Petroška et al., unpublished data) supports the findings of the present assay about a substantial level of ERG homogeneity in multifocal PCa.

The occurrence of *TMPRSS2 : ERG* fusion in prostate carcinomas has been analysed in numerous studies (reviewed in 4). However, data on the heterogeneity of *TMPRSS2 : ERG* fusion in multifocal PCa are really limited. Barry et al. (26) analysed 32 multifocal PCa cases and found fusion heterogeneity in 41% of them. In the study of Mehra et al. (27), 43 cases were analysed, and 70% of them showed heterogeneity. Both studies were done by means of FISH, and the heterogeneity of the fusion status was understood as either the presence or absence of fusion or the occurrence of *TMPRSS2* rearrangements through different genetic events (translocation or deletion). None of these

studies evaluated the *TMPRSS2 : ERG* expression level or assessed fusion variants. In our study, using RT-PCR and QPCR, a high heterogeneity of *TMPRSS2 : ERG* transcripts was detected, and the expression levels also differed among the foci. In our study, 6 out of 8 pairs of tumours from multifocal PCa expressed different variants of *TMPRSS2 : ERG*, and two additional pairs showed a varying status of fusion positivity. Notably, several recent studies (5–9) have shown significant associations between *TMPRSS2 : ERG* positivity and the aggressive course of PCa. Expression of specific splice variants of *TMPRSS2 : ERG* or occurrence of fusion duplication (6, 7, 9) were shown as indicators of aggressive PCa behaviour; thus, identification of *TMPRSS2 : ERG*-positive foci in prostate tumours may assist in predicting the clinical outcome of the disease.

In our study, some association was identified between the expression of *TERT*, encoding the main subunit of telomerase, and tumour positivity for *TMPRSS2 : ERG* which suggests a possible association between these two oncogenic transcripts involved in prostate pathogenesis. Telomerase is a reverse transcriptase responsible for the elongation of chromosomal ends or telomeres. Telomeres are important components of molecular pathways involved in cell senescence and the control of the cell cycle. In PCa, telomerase activity has been detected in 47% to 100% of PCa cases (28). We used a RT-PCR-based approach for detecting the transcript and identified *TERT* in 11 of 20 (55%) tumour foci of PCa patients. Our results are in line with the data of other studies (29, 30) and for the first time show a considerable heterogeneity of multifocal prostate tumours according to *TERT* expression. A recent study (31) has revealed that human prostate tumours contain a cancer progenitor cell subpopulation which can be indicated by an elevated telomerase activity. The aggressiveness of tumour foci is significantly influenced by the amount of progenitor cells which can be evaluated by measuring *TERT* expression.

One case of biochemical progression was identified among multifocal tumours involved in our study. Results of molecular tests suggested an aggressive outcome based on the assessment of one focus, while another focus showed a non-aggressive molecular pattern – a low production of *TMPRSS2 : ERG* transcript and negativity for *TERT*. In this particular case, molecular analysis of two foci from multifocal PCa provided more accurate data on the possible biological behaviour of the tumour than those expected from the analysis of a single focus.

## CONCLUSIONS

Our study revealed pronounced levels of heterogeneity in the expression of oncogenic transcripts related to prostate carcinogenesis in separate tumour foci from PCa

patients. IHC biomarkers were less heterogeneous in the PCa of these cases. The application of molecular tests, particularly measurement of *TMPRSS2 : ERG* and *TERT* expression, offers a valuable tool for the identification of most aggressive tumour foci and selection of a relevant PCa treatment.

## ACKNOWLEDGEMENTS

The study was supported by the Lithuanian State Science and Studies Foundation (grant C-03/2007).

Received 2 December 2011

Accepted 23 December 2011

## References

1. Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. *Hum Pathol.* 2010; 41(6): 781–93.
2. Meiers I, Waters DJ, Bostwick DG. Preoperative prediction of multifocal prostate cancer and application of focal therapy: review 2007. *Urology.* 2007; 70(6 Suppl): 3–8.
3. Karavitakis M, Ahmed HU, Abel PD, Hazell S, Winkler MH. Tumor focality in prostate cancer: implications for focal therapy. *Nat Rev Clin Oncol.* 2011; 8(1): 48–55.
4. Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. *Eur Urol.* 2009; 56(2): 275–86.
5. Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang LY et al. Expression of the *TMPRSS2 : ERG* fusion gene predicts cancer recurrence after surgery for localized prostate cancer. *Br J Cancer.* 2007; 97(12): 1690–5.
6. Hu Y, Dobi A, Sreenath T, Cook C, Tadase AY, Ravindranath L et al. Delineation of *TMPRSS2-ERG* splice variants in prostate cancer. *Clin Cancer Res.* 2008; 14(15): 4719–25.
7. Wang J, Cai Y, Yu W, Ren C, Spencer DM, Ittmann M. Pleiotropic biological activities of alternatively spliced *TMPRSS2 / ERG* fusion gene transcripts. *Cancer Res.* 2008; 68(20): 8516–24.
8. Demichelis F, Fall K, Perner S, Andr n O, Schmidt F, Setlur SR et al. *TMPRSS2 : ERG* gene fusion associated with lethal prostate cancer in a watchful waiting cohort. *Oncogene.* 2007; 26(31): 4596–9.
9. Attard G, Clark J, Ambrosine L, Fisher G, Kovacs G, Flohr P et al. Duplication of the fusion of *TMPRSS2* to *ERG* sequences identifies fatal human prostate cancer. *Oncogene.* 2008; 27(3): 253–63.

10. Joshua AM, Evans A, Van der Kwast T, Zielenska M, Meeker AK, Chinnaiyan A, Squire JA. Prostatic preneoplasia and beyond. *Biochim Biophys Acta*. 2008; 1785(2): 156–81.
11. Sabaliauskaitė R, Jarmalaitė S, Petroška D, Dasevičius D, Laurinavičius A, Jankevičius F, Lazutka JR. Expression of *TMPRSS2* : *ERG* and *TERT* identifies a subgroup of prostate carcinomas with increased risk of biochemical recurrence (manuscript).
12. Rubin MA, Bismar TA, Andrén O, Mucci L, Kim R, Shen R et al. Decreased A-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. *Cancer Epidemiol Biomarkers Prev*. 2005; 14(6): 1424–32.
13. Burke PA, Gregg JP, Bakhtiar B, Beckett LA, Denardo GL, Albrecht H et al. Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules. *Int J Oncol*. 2006; 29(1): 49–55.
14. Nariculam J, Freeman A, Bott S, Munson P, Cable N, Brookman-Amisshah N et al. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors. *Asian J Androl*. 2009; 11(1): 109–18.
15. Kufe DW. Mucins in cancer: function, prognosis and therapy. *Nat Rev Cancer*. 2009; 9(12): 874–85.
16. Kumaresan K, Kakkar N, Verma A, Mandal AK, Singh SK, Joshi K. Diagnostic utility of  $\alpha$ -methylacyl CoA racemase (P504S) and HMWCK in morphologically difficult prostate cancer. *Diagn Pathol*. 2010; 5: 83.
17. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. *Neoplasia*. 2010; 12(7): 590–8.
18. Falzarano SM, Zhou M, Carver P, Tsuzuki T, Simmerman K, He H, Magi-Galluzzi C. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. *Virchows Arch*. 2011; 459(4): 441–7.
19. Rubin MA, Dunn R, Strawderman M, Pienta KJ. Tissue microarray sampling strategy for prostate cancer biomarker analysis. *Am J Surg Pathol*. 2002; 26(3): 312–9.
20. Dancau AM, Simon R, Mirlacher M, Sauter G. Tissue microarrays. *Methods Mol Biol*. 2010; 576: 49–60.
21. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al. Recurrent fusion of *TMPRSS2* and *ETS* transcription factor genes in prostate cancer. *Science*. 2005; 310(5748): 644–8.
22. Boltze C, Mundschenk J, Unger N, Schneider-Stock R, Peters B, Mawrin C et al. Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma. *J Clin Endocrinol Metab*. 2003; 88(9): 4280–6.
23. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Cheng L. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. *Cancer*. 2004; 100(11): 2362–6.
24. Aihara M, Wheeler TM, Ohori M, Scardino PT. Heterogeneity of prostate cancer in radical prostatectomy specimens. *Urology*. 1994; 43(1): 60–6.
25. Borre M, Stausbol-Gron B, Overgaard J. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. *J Urol*. 2000; 164(3 Pt 1): 716–21.
26. Barry M, Perner S, Demichelis F, Rubin MA. *TMPRSS2*-*ERG* fusion heterogeneity in multifocal prostate cancer: clinical and biological implications. *Urology*. 2007; 70(4): 630–3.
27. Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ et al. Heterogeneity of *TMPRSS2* gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. *Cancer Res*. 2007; 67(17): 7991–5.
28. Meeker AK. Telomeres and telomerase in prostatic intraepithelial neoplasia and prostate cancer biology. *Urol Oncol*. 2006; 24(2): 122–30.
29. Latil A, Vidaud D, Valeri A, Fournier G, Vidaud M, Lidereau R et al. htert expression correlates with *myc* overexpression in human prostate cancer. *Int J Cancer*. 2000; 89(2): 172–6.
30. Kamradt J, Drosse C, Kalkbrenner S, Rohde V, Lensch R, Lehmann J et al. Telomerase activity and telomerase subunit gene expression levels are not related in prostate cancer: a real-time quantification and *in situ* hybridization study. *Lab Invest*. 2003; 83(5): 623–33.
31. Xu T, He K, Wang L, Goldkorn A. Prostate tumor cells with cancer progenitor properties have high telomerase activity and are rapidly killed by telomerase interference. *Prostate*. 2011; 71(13): 1390–400.



Rasa Sabaliauskaitė, Donatas Petroška, Darius Dasevičius,  
Arvydas Laurinavičius, Feliksas Jankevičius, Juozas R. Lazutka,  
Sonata Jarmalaitė

## DAUGIAŽIDINIŲ PROSTATOS NAVIKŲ MOLEKULINIAI TYRIMAI

### *Santrauka*

**Įvadas.** Prostatos navikai (PN) dažniausiai yra daugiažidiniai, nes histologiškai ir molekulinio profilio besiskiriantys naviko židiniai formuojasi iš karto keliose prostatos srityse. Prostatos vėžio diagnozė grindžiama patologiiniu biopsijos mėginio tyrimu, tačiau šis mėginys neretai neatspindi visų piktybėjimo židinių charakteristikų. Tiksliam ligos eigos prognozavimui būtini žymenys, apibūdinantys individualius daugiažidinius PN ir įvertinantys jų agresyvumą.

**Medžiagos ir metodai.** Dešimtyje daugiažidinių pT2 ir pT3 stadijos navikų tirta po du nutolusius navikinius židinius. *TMPRSS2 : ERG*, *TMPRSS2 : ETV1* ir *TERT* raiška nustatyta at-

virkštinės transkripcijos PGR, kiekybinei raiškai įvertinti naudotas realaus laiko PGR metodas. Ki-67, ERG, EMA, AMACR, p16 ir p53 baltymų raiška tirta imunohistochemiškai audinių mikrogardelėse.

**Rezultatai.** Skirtingos diferenciacijos pagal *Gleason* skalę naviko židiniai nustatyti dviejuose iš dešimties daugiažidinių PN. Daugumos imunohistocheminių (IHC) žymenų raiška buvo homogeniška skirtinguose to paties naviko židiniuose, tačiau 44 % (4 iš 9) PN nustatyta skirtinga p16 baltymo raiška. 80 % (8 iš 10) daugiažidinių PN nustatyti *TMPRSS2 : ERG* raiškos skirtumai – sulietinio transkripto izoformų įvairovė, skirtingas raiškos intensyvumas arba transkriptas buvo nustatomas tik viename židinyje. 90 % (9 iš 10) PN pasižymėjo skirtinga *TERT* raiška tirtuose poriniuose židiniuose.

**Išvados.** *TMPRSS2 : ERG* ir *TERT* transkriptų nustatymas gali būti naudojamas aptinkant agresyvius PN židinius, taip pat siekiant parinkti tinkamiausią gydymo strategiją.

**Raktažodžiai:** prostatos vėžys, daugiažidiniai navikai, *TMPRSS2 : ERG*, telomerazė